NON SMALL CELL LUNG CANCER, PLEURAL MESOTHELIOMA research hub

A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes

This study looks at a new combination of two medicines, niraparib and dostarlimab, for people with a type of lung cancer called pleural mesothelioma. Researchers want to see if this treatment can stop the cancer from growing for longer periods.